Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial-Reference-Cited by-同舟云学术

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

Published:2011-02 Issue:2 Volume:12 Page:144-152
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Hansson Johan,Aamdal Steinar,Bastholt Lars,Brandberg Yvonne,Hernberg Micaela,Nilsson Bo,Stierner Ulrika,von der Maase Hans

Publisher

Elsevier BV

Subject

Oncology

Reference13 articles.

1. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma;Balch;J Clin Oncol,2001

2. Interferon alfa-2b adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials;Wheatley;J Clin Oncol,2007

3. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684;Kirkwood;J Clin Oncol,1996

4. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190;Kirkwood;J Clin Oncol,2000

5. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial;Cascinelli;Lancet,2001

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Therapy for Melanoma: ASCO Guideline Update;Journal of Clinical Oncology;2023-10-20

2. Immunotherapy Options for Acral Melanoma, A fast-growing but Neglected Malignancy;Archives of Medical Research;2022-12

3. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022;European Journal of Cancer;2022-07

4. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma;Cellular & Molecular Immunology;2022-04-22

5. Malignes Melanom und andere Hauttumoren;Allgemein- und Viszeralchirurgie I;2022